Showing results (81-90 of 103) with videos related to

Sort By:
Pageof 11
European Cytokine Network|June 12, 2001
Can interleukin-2 reverse anthracyclin chemoresistance in metastatic soft tissue sarcoma patients. Results of a prospective phase II clinical trialG Gravis, M Mousseau, J Y Douillard, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
A study of the expression of four chemoresistance-related genes in human primary and metastatic brain tumoursM Mousseau, C Chauvin, M F Nissou, et al.
Urologic Oncology|January 13, 2011
Rapidly recycled, intensive alternating chemotherapy in heavily pretreated progressive nonseminomatous germ cell tumors a feasibility studyS Culine, J P Droz, R Delva, et al.
Bulletin Du Cancer|April 16, 1998
[Evaluation of the diagnostic usefulness of CA125 immunoscintigraphy for ovarian carcinoma follow-up after treatment: contribution of this technique in Grenoble University Medical Center]J P Vuillez, E Levrot, M Mousseau, et al.
Bulletin Du Cancer. Radiotherapie : Journal De La Societe Francaise Du Cancer : Organe De La Societe Francaise De Radiotherapie Oncologique|January 1, 1990
[Association of 5-FU, CDDP and hypofractionated radiotherapy in recurrences of subtentorial astrocytomas and malignant gliomas in adults]M Bolla, P Vincent, A Benabid, et al.
American Journal of Clinical Oncology|April 25, 2000
Randomized comparison of prophylactic antidiarrheal treatment versus no prophylactic antidiarrheal treatment in patients receiving CPT-11 (irinotecan) for advanced 5-FU-resistant colorectal cancer: an open-label multicenter phase II studyM Ychou, J Y Douillard, P Rougier, et al.
Bulletin Du Cancer|December 1, 1994
[Modulation of indications of adjuvant hormone therapy with tamoxifen in T1T2/N0N1 breast cancers. Preliminary results of a multicenter study with 695 cases]M Bolla, M Mousseau, P Winckel, et al.
Oncology|July 4, 2006
Randomised trial comparing three different schedules of infusional 5FU and raltitrexed alone as first-line therapy in metastatic colorectal cancer. Final results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 trialM Ducreux, O Bouche, J P Pignon, et al.
The New England Journal of Medicine|May 1, 1998
Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'ImmunothérapieS Negrier, B Escudier, C Lasset, et al.
European Journal of Cancer (Oxford, England : 1990)|November 5, 2013
A phase III adjuvant randomised trial of 6 cycles of 5-fluorouracil-epirubicine-cyclophosphamide (FEC100) versus 4 FEC 100 followed by 4 Taxol (FEC-T) in node positive breast cancer patients (Trial B2000)C Delbaldo, D Serin, M Mousseau, et al.
Pageof 11